BioMed Research International

Molecular Imaging-Guided Theranostics and Personalized Medicine


Publishing date
13 Sep 2013
Status
Published
Submission deadline
03 May 2013

Lead Editor

1University of Texas MD Anderson Cancer Center, Houston, TX, USA

2Taipei Medical University and Neurosurgery and Surgery, University of California, Irvine, CA, USA

3Yokohama City University School of Medicine, 3-9 Fukuura Kanazawa-ku, Yokohama, Japan

4Radiopharmaceuticals Production and Marketing Center, Institute of Nuclear Energy Research, Atomic Energy Council, Taiwan

5Department of Nuclear Medicine, Ren Ji hospital, Shanghai JiaoTong University School of Medicine, China


Molecular Imaging-Guided Theranostics and Personalized Medicine

Description

The rapid increase in the market for molecular imaging science enhances the opportunities in the development of new molecular imaging agents for diagnosis and therapy. New clinical indications using proteomic or genomic expression in oncology, as well as cardiology and neurology, also offer a stimulus. This promotes growth of procedure volume and sales of clinic imaging agents as well as development of new radiopharmaceuticals. The growing use of molecular imaging is also helping to control and monitor dosage for increased safety and effectiveness. For instance, molecular imaging in oncology has been focused on identification of tumor specific markers and the application of these markers for evaluation of patient response to radiation therapy, chemotherapy, or chemo/radiotherapy. Therefore, molecular imaging technologies play a major role to be able to provide personalized therapy for patients. The opportunity to use image-guiding to select patient for personalized therapy is truly the focus. The imaging findings could be integrated with metabolomics. In addition, theranostic concept is equally important in personalized therapy of diseases. The effort in image-guided cell therapy, theranostic approaches in parallel with instrumentation development, would be more accurate in the evaluation of patient response to treatment.

This special issue will provide new trends in molecular imaging agents and instrumentation development. This special issue will become the scientific tool for moving a concept from bench work to clinic product development. The special issue will be interesting to translational research scientists and support staff, such as clinicians, molecular biologists, imaging scientists, pharmaceutical developers, physicists, fellows, and staffs. Both academic and clinical scientists are invited to submit the manuscripts. Potential topics include, but are not limited to:

  • Image-guided theranostic approach of diseases
  • Advances in bioimaging applications in preclinical drug discovery
  • Advances in imaging instrumentation development
  • Hybrid imaging modalities in disease management
  • Theranostic agents development
  • Imaging technology in drug development
  • Validation of imaging agents on new molecular targets
  • Personalized drug development from molecular imaging
  • Link metabolomics and imaging molecular pathways

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/bmri/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/bmri/molecular.imaging/mig/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2013
  • - Article ID 859453
  • - Editorial

Molecular Imaging-Guided Theranostics and Personalized Medicine

David J. Yang | Fong Y. Tsai | ... | Shaoli Song
  • Special Issue
  • - Volume 2013
  • - Article ID 964034
  • - Research Article

In Vivo Evidence of Increased nNOS Activity in Acute MPTP Neurotoxicity: A Functional Pharmacological MRI Study

Tiing Yee Siow | Chiao-Chi V. Chen | ... | Chen Chang
  • Special Issue
  • - Volume 2013
  • - Article ID 549359
  • - Research Article

Molecular Imaging of Nonsmall Cell Lung Carcinomas Expressing Active Mutant EGFR Kinase Using PET with [124I]-Morpholino-IPQA

Skye Hsin-Hsien Yeh | Chien-Feng Lin | ... | Ren-Shyan Liu
  • Special Issue
  • - Volume 2013
  • - Article ID 460619
  • - Research Article

Synthesis and Biological Evaluation of O-[3-18F-fluoropropyl]-α-methyl Tyrosine in Mesothelioma-Bearing Rodents

I-Hong Shih | Fan-Lin Kong | ... | David J. Yang
  • Special Issue
  • - Volume 2013
  • - Article ID 503095
  • - Research Article

Affinity Labeling of Membrane Receptors Using Tissue-Penetrating Radiations

Franklin C. Wong | John Boja | ... | Dean F. Wong
  • Special Issue
  • - Volume 2013
  • - Article ID 935351
  • - Clinical Study

Kidney Dosimetry in 177Lu and 90Y Peptide Receptor Radionuclide Therapy: Influence of Image Timing, Time-Activity Integration Method, and Risk Factors

F. Guerriero | M. E. Ferrari | ... | M. Cremonesi
  • Special Issue
  • - Volume 2013
  • - Article ID 597253
  • - Research Article

The Adjunctive Digital Breast Tomosynthesis in Diagnosis of Breast Cancer

Tsung-Lung Yang | Huei-Lung Liang | ... | Huay-Ben Pan
  • Special Issue
  • - Volume 2013
  • - Article ID 626910
  • - Review Article

Managing Lymphoma with Non-FDG Radiotracers: Current Clinical and Preclinical Applications

Fan-Lin Kong | Richard J. Ford | David J. Yang
  • Special Issue
  • - Volume 2013
  • - Article ID 348167
  • - Review Article

Clinical Application of Magnetic Resonance Imaging in Management of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Jeon-Hor Chen | Min-Ying Su
  • Special Issue
  • - Volume 2013
  • - Article ID 970586
  • - Review Article

Advanced MR Imaging of Gliomas: An Update

Hung-Wen Kao | Shih-Wei Chiang | ... | Cheng-Yu Chen
BioMed Research International
 Journal metrics
Acceptance rate31%
Submission to final decision67 days
Acceptance to publication30 days
CiteScore3.600
Impact Factor2.276
 Submit

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.